CS/BSE&NSE/PR/2020-2021
26th August, 2020

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239
Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: News Release

With reference to above subject, please find enclosed News Release of our company Titled “Suven Life Sciences announces five poster presentations including Phase-2 proof-of-concept study design for SUVN-G3031 in patients with narcolepsy at the SLEEP 2020 virtual conference.”

This is for your information and record.

Thanking you,
Yours faithfully,
For Suven Life Sciences Limited

Shrenik Soni
Company Secretary
Encl.: As above
Suven Life Sciences announces five poster presentations including Phase-2 proof-of-concept study design for SUVN-G3031 in patients with narcolepsy at the SLEEP 2020 virtual conference

Published: 26-Aug-2020, Hyderabad, India

Suven Life Sciences announced today that five posters on SUVN-G3031, a histamine-3 receptor inverse agonist will be presented at the upcoming 34th Annual Meeting of the Associated Professional Sleep Societies (APSS), known as "SLEEP 2020." The meeting will be held virtually from August 27-30, 2020.

The poster presentations include a Phase-2 proof-of-concept study design that is currently recruiting the patients with narcolepsy with and without cataplexy, pharmacokinetic profile and safety findings from Phase-1 study, preclinical efficacy and differentiating features over current treatments of narcolepsy.

Details of the poster presentations are as below:

- Phase-2 proof of concept study of SUVN-G3031, a histamine H3 receptor inverse agonist for the potential treatment of narcolepsy (Poster 0759)
- SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist: Safety, tolerability and pharmacokinetics following single and multiple ascending doses in healthy adult subjects (Poster 0760)
- SUVN-G3031, A histamine H3 receptor inverse agonist produces robust wake promoting and antcataplectic activity in orexin knockout mice (Poster 0008)
- Preclinical characterization of SUVN-G3031, A histamine H3 receptor inverse agonist for the treatment of narcolepsy (Poster 0072)
- SUVN-G3031, A potent and selective histamine H3 receptor inverse agonist - Differentiating features over current treatments of narcolepsy (Poster 0155)

Update on SUVN-G3031 Phase-2 proof-of-concept study:

- Patient recruitment for the study is currently ongoing in USA.
- Data readout from Phase-2 POC study is estimated in early 2021.

SUVN-G3031 is being evaluated as monotherapy for the safety, tolerability, pharmacokinetics, and efficacy at doses of 2 mg and 4 mg compared to placebo in patients with narcolepsy with and without cataplexy. The primary objective of this study is to demonstrate superiority of SUVN-G3031 compared to placebo as measured by an improvement in the Maintenance of Wakefulness Test (MWT) score.
About SUVN-G3031: SUVN-G3031 is a potent, selective and well differentiated Histamine H3 receptor inverse agonist with excellent oral bioavailability and drug-like properties. It enhances the in-vivo release of several neurotransmitters in the cortex and showed robust wake promoting effects in various animal models. SUVN-G3031 has excellent safety profile in preclinical models with no propensity to induce abuse liability. SUVN-G3031 has successfully completed two phase-1 studies in USA in 72 healthy adult and elderly male/female populations with no serious adverse events.

About Suven Life Sciences: Suven Life Sciences is a clinical-stage biopharmaceutical company with the objective of development and commercialization of novel therapeutics for the treatment of central nervous system (CNS) disorders. Suven's clinical candidates Masupirdine (SUVN-502), SUVN-G3031, SUVN-D4010 and SUVN-911 are at various stages of clinical development. Several other developmental compounds including SUVN-I6107 an M1 PAM for treating cognitive deficits, SUVN-M8036 a multimodal compound for treating psychosis/schizophrenia and SUVN-D1044 for treating gastro-intestinal disorders are at advanced preclinical stage of development.

For more information please visit our Web site at http://www.suven.com

Disclaimer and Risk Statement: Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.